|
1
|
Saeedi P, Petersohn I, Salpea P, Malanda
B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA,
Ogurtsova K, et al: Global and regional diabetes prevalence
estimates for 2019 and projections for 2030 and 2045: Results from
the International Diabetes Federation Diabetes Atlas,
9th edition. Diabetes Res Clin Pract.
157(107843)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
de Vegt F, Dekker JM, Jager A, Hienkens E,
Kostense PJ, Stehouwer CDA, Nijpels G, Bouter LM and Heine RJ:
Relation of impaired fasting and postload glucose with incident
type 2 diabetes in a Dutch population: The Hoorn Study. JAMA.
285:2109–2113. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Harris MI: Impaired glucose tolerance in
the U.S. population. Diabetes Care. 12:464–474. 1989.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Edelstein SL, Knowler WC, Bain RP, Andres
R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD,
Muller DC, et al: Predictors of progression from impaired glucose
tolerance to NIDDM: An analysis of six prospective studies.
Diabetes. 46:701–710. 1997.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Huang Y, Cai X, Mai W, Li M and Hu Y:
Association between prediabetes and risk of cardiovascular disease
and all cause mortality: Systematic review and meta-analysis. BMJ.
355(i5953)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gong Q, Zhang P, Wang J, An Y, Gregg EW,
Li H, Zhang B, Shuai Y, Yang W, Chen Y, et al: Changes in mortality
in people with IGT before and after the onset of diabetes during
the 23-year follow-up of the Da Qing Diabetes Prevention Study.
Diabetes Care. 39:1550–1555. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tuomilehto J, Lindström J, Eriksson JG,
Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S,
Laakso M, Louheranta A, Rastas M, et al: Prevention of type 2
diabetes mellitus by changes in lifestyle among subjects with
impaired glucose tolerance. N Engl J Med. 344:1343–1350.
2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Knowler WC, Barrett-Connor E, Fowler SE,
Hamman RF, Lachin JM, Walker EA and Nathan DM: Diabetes Prevention
Program Research Group. Reduction in the incidence of type 2
diabetes with lifestyle intervention or metformin. N Engl J Med.
346:393–403. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ramachandran A, Snehalatha C, Mary S,
Mukesh B, Bhaskar AD and Vijay V: Indian Diabetes Prevention
Programme (IDPP). The Indian Diabetes Prevention Programme shows
that lifestyle modification and metformin prevent type 2 diabetes
in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Diabetologia. 49:289–297. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Holman RR, Coleman RL, Chan JCN, Chiasson
JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, et al:
Effects of acarbose on cardiovascular and diabetes outcomes in
patients with coronary heart disease and impaired glucose tolerance
(ACE): A randomised, double-blind, placebo-controlled trial. Lancet
Diabetes Endocrinol. 5:877–886. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
DREAM (Diabetes REduction Assessment with
ramipril and rosiglitazone Medication) Trial Investigators.
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N,
Hanefeld M, Hoogwerf B, Laakso M, et al: Effect of rosiglitazone on
the frequency of diabetes in patients with impaired glucose
tolerance or impaired fasting glucose: A randomised controlled
trial. Lancet. 368:1096–1105. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
DeFronzo RA, Tripathy D, Schwenke DC,
Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN,
Kitabchi AE, et al: Pioglitazone for diabetes prevention in
impaired glucose tolerance. N Engl J Med. 364:1104–1115.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pi-Sunyer X, Astrup A, Fujioka K, Greenway
F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R,
Jensen CB, et al: A randomized, controlled trial of 3.0 mg of
liraglutide in weight management. N Engl J Med. 373:11–22.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Blonde L and Russell-Jones D: The safety
and efficacy of liraglutide with or without oral antidiabetic drug
therapy in type 2 diabetes: An overview of the LEAD 1-5 studies.
Diabetes Obes Metab. 11 (Suppl 3):S26–S34. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rizzo M, Nikolic D, Patti AM, Mannina C,
Montalto G, McAdams BS, Rizvi AA and Cosentino F: GLP-1 receptor
agonists and reduction of cardiometabolic risk: Potential
underlying mechanisms. Biochim Biophys Acta Mol Basis Dis.
1864:2814–2821. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Vergès B and Charbonnel B: After the
LEADER trial and SUSTAIN-6, how do we explain the cardiovascular
benefits of some GLP-1 receptor agonists? Diabetes Metab. 43 (Suppl
1):2S3–2S12. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nauck MA, Quast DR, Wefers J and Meier JJ:
GLP-1 receptor agonists in the treatment of type 2
diabetes-state-of-the-art. Mol Metab. 46(101102)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Noyan-Ashraf MH, Shikatani EA, Schuiki I,
Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker
DJ and Husain M: A glucagon-like peptide-1 analog reverses the
molecular pathology and cardiac dysfunction of a mouse model of
obesity. Circulation. 127:74–85. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Simanenkova A, Minasian S, Karonova T,
Vlasov T, Timkina N, Shpilevaya O, Khalzova A, Shimshilashvili A,
Timofeeva V, Samsonov D, et al: Comparative evaluation of metformin
and liraglutide cardioprotective effect in rats with impaired
glucose tolerance. Sci Rep. 11(6700)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shareef M, Saleh L, van den Meiracker AH
and Visser W: The impact of implementing the WHO-2013 criteria for
gestational diabetes mellitus on its prevalence and pregnancy
outcomes: A comparison of the WHO-1999 and WHO-2013 diagnostic
thresholds. Eur J Obstet Gynecol Reprod Biol. 246:14–18.
2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Penn L, White M, Oldroyd J, Walker M,
Alberti KG and Mathers JC: Prevention of type 2 diabetes in adults
with impaired glucose tolerance: The European Diabetes Prevention
RCT in Newcastle upon Tyne, UK. BMC Public Health.
9(342)2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mann J, Lean M, Toeller M, Slama G,
Uusitupa M and Vessby B: Recommendations for the nutritional
management of patients with diabetes mellitus. Eur J Clin Nutr.
54:353–355. 2000.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lee MY, Fraser JD, Chapman MJ,
Sundararajan K, Umapathysivam MM, Summers MJ, Zaknic AV, Rayner CK,
Meier JJ, Horowitz M and Deane AM: The effect of exogenous
glucose-dependent insulinotropic polypeptide in combination with
glucagon-like peptide-1 on glycemia in the critically ill. Diabetes
Care. 36:3333–3336. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
DeLong DM, DeLong ER, Wood PD, Lippel K
and Rifkind BM: A comparison of methods for the estimation of
plasma low- and very low-density lipoprotein cholesterol: The Lipid
Research Clinics Prevalence Study. JAMA. 256:2372–2377.
1986.PubMed/NCBI
|
|
25
|
Ruzicka K, Veitl M, Thalhammer-Scherrer R
and Schwarzinger I: The new hematology analyzer Sysmex XE-2100:
Performance evaluation of a novel white blood cell differential
technology. Arch Pathol Lab Med. 125:391–396. 2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rizzo M, Chandalia M, Patti AM, Di Bartolo
V, Rizvi AA, Montalto G and Abate N: Liraglutide decreases carotid
intima-media thickness in patients with type 2 diabetes: 8-month
prospective pilot study. Cardiovasc Diabetol. 13(49)2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Corrado E, Rizzo M, Tantillo R, Muratori
I, Bonura F, Vitale G and Novo S: Markers of inflammation and
infection influence the outcome of patients with baseline
asymptomatic carotid lesions: A 5-year follow-up study. Stroke.
37:482–486. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
La Sala L, Prattichizzo F and Ceriello A:
The link between diabetes and atherosclerosis. Eur J Prev Cardiol.
26:15–24. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pankow JS, Kwan DK, Duncan BB, Schmidt MI,
Couper DJ, Golden S and Ballantyne CM: Cardiometabolic risk in
impaired fasting glucose and impaired glucose tolerance: The
Atherosclerosis Risk in Communities Study. Diabetes Care.
30:325–331. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Magliano DJ, Soderberg S, Zimmet PZ,
Cartensen B, Balkau B, Pauvaday V, Kowlessur S, Tuomilehto J,
Alberti KG and Shaw JE: Mortality, all-cause and cardiovascular
disease, over 15 years in multiethnic mauritius: Impact of diabetes
and intermediate forms of glucose tolerance. Diabetes Care.
33:1983–1989. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Barr EL, Zimmet PZ, Welborn TA, Jolley D,
Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM,
et al: Risk of cardiovascular and all-cause mortality in
individuals with diabetes mellitus, impaired fasting glucose, and
impaired glucose tolerance: The Australian Diabetes, Obesity, and
Lifestyle Study (AusDiab). Circulation. 116:151–157.
2007.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gong Q, Zhang P, Wang J, Ma J, An Y, Chen
Y, Zhang B, Feng X, Li H, Chen X, et al: Morbidity and mortality
after lifestyle intervention for people with impaired glucose
tolerance: 30-year results of the Da Qing Diabetes Prevention
Outcome Study. Lancet Diabetes Endocrinol. 7:452–461.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Schuler G, Adams V and Goto Y: Role of
exercise in the prevention of cardiovascular disease: Results,
mechanisms, and new perspectives. Eur Heart J. 34:1790–1799.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chiasson JL, Josse RG, Gomis R, Hanefeld
M, Karasik A and Laakso M: Acarbose for prevention of type 2
diabetes mellitus: The STOP-NIDDM randomised trial. Lancet.
359:2072–2077. 2002.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Frías JP, Davies MJ, Rosenstock J, Pérez
Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X and Brown K:
SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly
in patients with type 2 diabetes. N Engl J Med. 385:503–515.
2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
GRADE Study Research Group. Nathan DM,
Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, Fortmann SP,
Green JB, Kahn SE, et al: Glycemia reduction in type 2 diabetes
microvascular and cardiovascular outcomes. N Engl J Med.
387:1075–1088. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sisson EM: Liraglutide: Clinical
pharmacology and considerations for therapy. Pharmacotherapy.
31:896–911. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Knudsen LB and Lau J: The discovery and
development of liraglutide and semaglutide. Front Endocrinol
(Lausanne). 10(155)2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gallwitz B: Glucagon-like peptide-1
analogues for type 2 diabetes mellitus. Drugs. 71:1675–1688.
2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lazzaroni E, Ben Nasr M, Loretelli C,
Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A,
Montefusco L, et al: Anti-diabetic drugs and weight loss in
patients with type 2 diabetes. Pharmacol Res.
171(105782)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Schwasinger-Schmidt T, Robbins DC,
Williams SJ, Novikova L and Stehno-Bittel L: Long-term liraglutide
treatment is associated with increased insulin content and
secretion in beta-cells, and a loss of alpha-cells in ZDF rats.
Pharmacol Res. 76:58–66. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Brohall G, Oden A and Fagerberg B: Carotid
artery intima-media thickness in patients with Type 2 diabetes
mellitus and impaired glucose tolerance: A systematic review.
Diabet Med. 23:609–616. 2006.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Henry RMA, Kostense PJ, Dekker JM, Nijpels
G, Heine RJ, Kamp O, Bouter LM and Stehouwer CDA: Carotid arterial
remodeling: A maladaptive phenomenon in type 2 diabetes but not in
impaired glucose metabolism: The Hoorn study. Stroke. 35:671–676.
2004.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Henry RMA, Kostense PJ, Spijkerman AMW,
Dekker JM, Nijpels G, Heine RJ, Kamp O, Westerhof N, Bouter LM and
Stehouwer CD: Hoorn Study. Arterial stiffness increases with
deteriorating glucose tolerance status. Circulation. 107:2089–2095.
2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bonora E, Kiechl S, Oberhollenzer F, Egger
G, Bonadonna RC, Muggeo M and Willeit J: Impaired glucose
tolerance, Type II diabetes mellitus and carotid atherosclerosis:
Prospective results from the Bruneck Study. Diabetologia.
43:156–164. 2000.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Williams B, Mancia G, Spiering W, Agabiti
Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G,
Dominiczak A, et al: 2018 ESC/ESH Guidelines for the management of
arterial hypertension. Eur Heart J. 39:3021–3104. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Munzel T, Gori T, Bruno RM and Taddei S:
Is oxidative stress a therapeutic target in cardiovascular disease?
Eur Heart J. 31:2741–2748. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Tabas I and Bornfeldt KE: Macrophage
phenotype and function in different stages of atherosclerosis. Circ
Res. 118:653–667. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hattori Y, Jojima T, Tomizawa A, Satoh H,
Hattori S, Kasai K and Hayashi T: A glucagon-like peptide-1 (GLP-1)
analogue, liraglutide, upregulates nitric oxide production and
exerts anti-inflammatory action in endothelial cells. Diabetologia.
53:2256–2263. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Shiraki A, Oyama J, Komoda H, Asaka M,
Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T and
Node K: The glucagon-like peptide 1 analog liraglutide reduces
TNF-α-induced oxidative stress and inflammation in endothelial
cells. Atherosclerosis. 221:375–382. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhang L, Tian J, Diao S, Zhang G, Xiao M
and Chang D: GLP-1 receptor agonist liraglutide protects
cardiomyocytes from IL-1β-induced metabolic disturbance and
mitochondrial dysfunction. Chem Biol Interact.
332(109252)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Chow BS, Koulis C, Krishnaswamy P,
Steckelings UM, Unger T, Cooper ME, Jandeleit-Dahm KA and Allen TJ:
The angiotensin II type 2 receptor agonist Compound 21 is
protective in experimental diabetes-associated atherosclerosis.
Diabetologia. 59:1778–1790. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Yeboah J, Young R, McClelland RL, Delaney
JC, Polonsky TS, Dawood FZ, Blaha MJ, Miedema MD, Sibley CT, Carr
JJ, et al: Utility of nontraditional risk markers in
atherosclerotic cardiovascular disease risk assessment. J Am Coll
Cardiol. 67:139–147. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Aatola H, Hutri-Kahonen N, Juonala M,
Viikari JS, Hulkkonen J, Laitinen T, Taittonen L, Lehtimaki T,
Raitakari OT and Kahonen M: Lifetime risk factors and arterial
pulse wave velocity in adulthood: the cardiovascular risk in young
Finns study. Hypertension. 55:806–811. 2010.PubMed/NCBI View Article : Google Scholar
|
